OptiNose is a drug delivery company to commercialize a novel nasal drug delivery system that achieves targeted delivery to sites that are poorly accessed by existing nasal sprays. The technology has the ability to effectively deliver drugs to specific sites within the nose, while uniquely preventing drug distribution to the lungs. The technology has been successfully tested in a number of clinical trials to date including gamma scintigraphy studies to confirm deposition, studies evaluating the immune response to conventional antigens and studies evaluating the delivery of CNS active compounds.